Mineralocorticoid receptor signalling in primary aldosteronism.


Journal

The Journal of endocrinology
ISSN: 1479-6805
Titre abrégé: J Endocrinol
Pays: England
ID NLM: 0375363

Informations de publication

Date de publication:
01 09 2023
Historique:
received: 07 10 2022
accepted: 24 07 2023
medline: 31 8 2023
pubmed: 24 7 2023
entrez: 24 7 2023
Statut: epublish

Résumé

Primary aldosteronism, or Conn syndrome, is the most common endocrine cause of hypertension. It is associated with a higher risk of cardiovascular, metabolic and renal diseases, as well as a lower quality of life than for hypertension due to other causes. The multi-systemic effects of primary aldosteronism can be attributed to aldosterone-mediated activation of the mineralocorticoid receptor in a range of tissues. In this review, we explore the signalling pathways of the mineralocorticoid receptor, with a shift from the traditional focus on the regulation of renal sodium-potassium exchange to a broader understanding of its role in the modulation of tissue inflammation, fibrosis and remodelling. The appreciation of primary aldosteronism as a multi-system disease with tissue-specific pathophysiology may lead to more vigilant testing and earlier institution of targeted interventions.

Identifiants

pubmed: 37486000
doi: 10.1530/JOE-22-0249
pii: e220249
doi:
pii:

Substances chimiques

Receptors, Mineralocorticoid 0
Mineralocorticoid Receptor Antagonists 0
Aldosterone 4964P6T9RB

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Jun Yang (J)

Centre of Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Department of Medicine, Monash University, Clayton, Victoria, Australia.

Morag J Young (MJ)

Cardiovascular Endocrinology Laboratory, Discovery & Preclinical Domain, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.

Timothy J Cole (TJ)

Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Peter J Fuller (PJ)

Centre of Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH